An interventional study of Fujirebio INNOTEST® HCV Ab IV assay in Hepatitis C Virus Infection, sponsored by Foundation for Innovative New Diagnostics, Switzerland. Completed at 2 sites in Ukraine. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-07-07.
Sponsored by Foundation for Innovative New Diagnostics, Switzerland · Not applicable, Interventional, and Diagnostic
The goal of this trial is to evaluate the performance of the Fujirebio INNOTEST® HCV Ab IV using simpler collection methods such as fingerstick and venous whole blood collection on dried blood spots (DBS). In order to assess performance in samples with high and low antibody titres, performance will be evaluated with undiluted samples of all trial participants and serial diluted samples for a subset of HCV antibody reactive samples. Serial dilution of reactive samples will provide further insights into the potential difference of sensitivity in samples collected on DBS versus plasma.
Results of this trial will also support the update of the regulatory claims to include DBS as an alternative sample type.
Access to Hepatitis C virus (HCV) screening in resource-limited settings should be enabled not only through the provision of point-of-care screening tests, but also through the possibility of collecting samples in decentralized settings One possible way of decentralizing sample collection is collecting dried blood spot (DBS) specimens, which can be easily transported to testing laboratories, not requiring any cold chain or complex sample transportation. DBS serology screening is complementary to established point-point-of care screening with rapid diagnostic tests, both methodologies being somewhat less cost-effective and less sensitive compared to lab-based methods but suitable for settings without sophisticated infrastructure.
To date, no HCV antibody serology test is formally evaluated for the use with DBS, however several studies on off-label use of DBS in serology screening assays, suggests that this sample type can serve as an alternative to plasma and serum. Fujirebio's enzyme immunoassay (EIA) INNOTEST® HCV Ab IV is CE marked and has received pre-qualification by the World Health Organization (WHO) for the use with venous plasma and serum, which require special equipment for sample collection, sample preparation and temperature controlled transportation.
Available data on the performance of HCV antibody detection from DBS samples are insufficient to introduce their use in clinical practice. Fujirebio is one of the few manufacturers who have an EIA test pre-qualified by the WHO for the use with plasma and serum to detect anti-HCV antibodies. A prospective diagnostic accuracy trial of the Fujirebio INNOTEST® HCV Ab IV assay in fWB and vWB collected on DBS, using EDTA plasma results obtained with the Fujirebio INNOTEST® HCV Ab IV assay as reference standard is needed to understand the relationship between results generated in plasma and WB samples collected on DBS. Furthermore, the data generated can be used by Fujirebio to update their regulatory claims and include DBS as an alternative sample type.
2,321 studies on the registry are indexed under Hepatitis C; 102 are open to participants now.
This study's enrollment of 300 is above the median of 79 across 1,633 interventional studies indexed under Hepatitis C.
Browse Hepatitis C studies →Foundation for Innovative New Diagnostics, Switzerland is the lead sponsor of 61 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Collection of whole blood via fingerstick and venipuncture
Device: Fujirebio INNOTEST® HCV Ab IV assay
Enzyme Immunoassay
Sensitivity and specificity of fingerstick whole blood DBS
Point estimates of sensitivity and specificity (with 95% confidence intervals) of the Fujirebio INNOTEST® HCV Ab IV assay in fWB collected on DBS, using EDTA plasma results obtained with the Fujirebio INNOTEST® HCV Ab IV assay as reference standard
Time frame: 4 months
Sensitivity and specificity of venous whole blood DBS
Point estimates of sensitivity and specificity (with 95% confidence intervals) of the Fujirebio INNOTEST® HCV Ab IV assay in vWB collected on DBS, using EDTA plasma results obtained with the Fujirebio INNOTEST® HCV Ab IV assay as reference standard
Time frame: 4 months
Degree of agreement of undiluted samples fWB and vWB
Point estimates of Cohen's Kappa Coefficient (ĸ) and negative, positive and overall rate of agreement of all undiluted samples for the Fujirebio INNOTEST® HCV Ab IV assay between fWB and vWB collected on DBS.
Time frame: 4 months
Degree of agreement of undiluted samples vWB and plasma
Point estimates of Cohen's Kappa Coefficient (ĸ) and negative, positive and overall rate of agreement of all undiluted samples for the Fujirebio INNOTEST® HCV Ab IV assay between vWB collected on DBS and plasma.
Time frame: 4 months
Degree of agreement of undiluted samples fWB and plasma
Point estimates of Cohen's Kappa Coefficient (ĸ) and negative, positive and overall rate of agreement of all undiluted samples for the Fujirebio INNOTEST® HCV Ab IV assay between fWB collected on DBS and plasma.
Time frame: 4 months
Degree of agreement of serial diluted samples fWB and vWB
Point estimates of Cohen's Kappa Coefficient (ĸ) and negative, positive and overall rate of agreement of serial-diluted HCV Ab positive samples for the Fujirebio INNOTEST® HCV Ab IV assay between fWB and vWB collected on DBS.
Time frame: 4 months
Degree of agreement of serial diluted samples vWB and plasma
Point estimates of Cohen's Kappa Coefficient (ĸ) and negative, positive and overall rate of agreement of serial-diluted HCV Ab positive samples for the Fujirebio INNOTEST® HCV Ab IV assay between vWB collected on DBS and plasma.
Time frame: 4 months
Degree of agreement of serial diluted samples fWB and plasma
Point estimates of Cohen's Kappa Coefficient (ĸ) and negative, positive and overall rate of agreement of serial-diluted HCV Ab positive samples for the Fujirebio INNOTEST® HCV Ab IV assay between fWB collected on DBS and plasma.
Time frame: 4 months
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Foundation for Innovative New Diagnostics, Switzerland